-

Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Arqit Quantum, Inc. (ARQQ, ARQQW) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Arqit Quantum, Inc. (“Arqit” or the “Company”) (NASDAQ: ARQQ, ARQQW). The investigation concerns whether Arqit has violated the federal securities laws and/or engaged in other unlawful business practices.

Arqit is a U.K. cybersecurity company that purports to have pioneered a unique quantum encryption technology which makes the communications links of any networked device secure against current and future forms of cyber attack, even an attack from a quantum computer.

Arqit went public in the U.S. on September 3, 2021, by merging with a special purpose acquisition company (“SPAC”). At the time, the Company projected it would rapidly become highly profitable, projecting $660 million in revenue in 2025. Shortly after the Company went public, the price of Arqit shares reached a high of $41.52 per share.

On April 18, 2022, before the market opened, the Wall Street Journal published an article entitled, “British Encryption Startup Arqit Overstates Its Prospects, Former Staff and Others Say.” The article reported that Arqit gave investors an overly optimistic view of its committed and future revenue and the readiness and workability of its encryption system. According to the article, “[P]eople familiar with the matter said that the bulk of the company’s committed revenue isn’t from selling its product and that at its public launch, the company had little more than an early-stage prototype of its encryption system.” On this news, the price of Arqit shares declined by $2.57 per share, or approximately 17.1%, from $15.06 per share to close at $12.49 per share on April 18, 2022.

If you purchased or otherwise acquired Arqit securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:ARQQ

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos...

IBRX ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your ImmunityBio investments, you have until May 26, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERE...

PYPL DEADLINE NOTICE: PayPal Holdings, Inc. Investors Encouraged to Contact Kirby McInerney LLP By April 20, 2026

NEW YORK--(BUSINESS WIRE)--If you suffered a loss on your investment inPayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ:PYPL), contact Lauren Molinaro by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 20, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff ove...
Back to Newsroom